Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Cemiplimab and Fianlimab before Surgery for the Treatment of Patients with Locally Advanced Kidney Cancer Undergoing Nephrectomy

Trial Status: active

This phase II trial tests how well cemiplimab and fianlimab before surgery (neoadjuvant) works in treating patients with clear cell renal cell carcinoma (kidney cancer) that has spread to nearby tissue or lymph nodes (locally advanced) undergoing nephrectomy (surgery to remove a kidney or part of a kidney). Immunotherapy with monoclonal antibodies, such as cemiplimab and fianlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This approach may be most effective before surgery while the cancer is still present and accessible to the immune cells and that these immune effects will prevent the cancer from coming back in the future. Giving cemiplimab and fianlimab before surgery may kill more tumor cells in treating patients with locally advanced kidney cancer.